Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy

To test the hypothesis that serum levels of soluble markers in children change after initiation of zidovudine therapy and that the extent and pattern of these longitudinal changes correlates with clinical outcome. We measured serum levels of soluble CD8, neopterin, beta 2-microglobulin (beta 2M), an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS (London) 1993-03, Vol.7 (3), p.369
Hauptverfasser: Siller, L, Martin, N L, Kostuchenko, P, Beckett, L, Rautonen, J, Cheng, S C, Wara, D W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page 369
container_title AIDS (London)
container_volume 7
creator Siller, L
Martin, N L
Kostuchenko, P
Beckett, L
Rautonen, J
Cheng, S C
Wara, D W
description To test the hypothesis that serum levels of soluble markers in children change after initiation of zidovudine therapy and that the extent and pattern of these longitudinal changes correlates with clinical outcome. We measured serum levels of soluble CD8, neopterin, beta 2-microglobulin (beta 2M), and p24 antigen, and CD4 cell counts, before the initiation of zidovudine therapy and at 12, 24 and 48 weeks of treatment in 24 HIV-1-infected children (Centers for Disease Control classification P2) and 15 controls. Soluble CD8 levels were elevated before therapy in 70% of the infected children; subsequent decreases were associated with lower risk of disease progression. The mean serum neopterin level before treatment was elevated in infected children; decreases in neopterin levels marginally reflected improved or stable clinical status. Serum beta 2M levels and CD4+ cell counts were not associated with clinical outcome. Only 10 out of the 24 patients had detectable levels of serum p24 antigen before treatment; again, the amount of decline after initiation of therapy did not predict clinical outcome. Decreasing levels of soluble CD8 and neopterin in HIV-1-infected children receiving zidovudine therapy might reflect a good response to treatment and a slowing of disease progression.
doi_str_mv 10.1097/00002030-199303000-00010
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_8097095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8097095</sourcerecordid><originalsourceid>FETCH-LOGICAL-p138t-61708069abb05d4630fed7bd0f1d49ce786ce366fb40921796b9a35d8c85da9e3</originalsourceid><addsrcrecordid>eNotkE1OwzAQhb0AlVI4ApIP0MA4Thx7WbX8VKrEorCu7HjSGqVxZCdFcBfuigUdafT0ZuZ7iyGEMrhnoKoHSJUDh4wpxZMCZKkZXJAp5EJlildwRa5j_EjjEqSckIlMIKhySn62GMYjbfGEbaS-odG3o2mRLldyTjv0_YDBdXNqcNA0z46uDn7fejO2rqO6s7TPi6SD22PykbrOuloPPvylWRdRR6R9ggLG6HyXLmh9cK0NCfh0w4Eu1qstTYtvZ_1ptK5DOhww6P7rhlw2uo14e9YZeX96fFu-ZJvX5_Vyscl6xuWQCVaBBKG0MVDaQnBo0FbGQsNsoWqspKiRC9GYAlTOKiWM0ry0spal1Qr5jNz95_ajOaLd9cEddfjand_EfwEWxWuH</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Siller, L ; Martin, N L ; Kostuchenko, P ; Beckett, L ; Rautonen, J ; Cheng, S C ; Wara, D W</creator><creatorcontrib>Siller, L ; Martin, N L ; Kostuchenko, P ; Beckett, L ; Rautonen, J ; Cheng, S C ; Wara, D W</creatorcontrib><description>To test the hypothesis that serum levels of soluble markers in children change after initiation of zidovudine therapy and that the extent and pattern of these longitudinal changes correlates with clinical outcome. We measured serum levels of soluble CD8, neopterin, beta 2-microglobulin (beta 2M), and p24 antigen, and CD4 cell counts, before the initiation of zidovudine therapy and at 12, 24 and 48 weeks of treatment in 24 HIV-1-infected children (Centers for Disease Control classification P2) and 15 controls. Soluble CD8 levels were elevated before therapy in 70% of the infected children; subsequent decreases were associated with lower risk of disease progression. The mean serum neopterin level before treatment was elevated in infected children; decreases in neopterin levels marginally reflected improved or stable clinical status. Serum beta 2M levels and CD4+ cell counts were not associated with clinical outcome. Only 10 out of the 24 patients had detectable levels of serum p24 antigen before treatment; again, the amount of decline after initiation of therapy did not predict clinical outcome. Decreasing levels of soluble CD8 and neopterin in HIV-1-infected children receiving zidovudine therapy might reflect a good response to treatment and a slowing of disease progression.</description><identifier>ISSN: 0269-9370</identifier><identifier>DOI: 10.1097/00002030-199303000-00010</identifier><identifier>PMID: 8097095</identifier><language>eng</language><publisher>England</publisher><subject>Acquired Immunodeficiency Syndrome - blood ; Acquired Immunodeficiency Syndrome - drug therapy ; beta 2-Microglobulin - analysis ; Biomarkers - blood ; Biopterins - analogs &amp; derivatives ; Biopterins - analysis ; CD4-Positive T-Lymphocytes ; CD8 Antigens - blood ; Child ; Child, Preschool ; Female ; HIV Core Protein p24 - blood ; Humans ; Infant ; Leukocyte Count ; Male ; Neopterin ; Predictive Value of Tests ; Prospective Studies ; Zidovudine - therapeutic use</subject><ispartof>AIDS (London), 1993-03, Vol.7 (3), p.369</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8097095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Siller, L</creatorcontrib><creatorcontrib>Martin, N L</creatorcontrib><creatorcontrib>Kostuchenko, P</creatorcontrib><creatorcontrib>Beckett, L</creatorcontrib><creatorcontrib>Rautonen, J</creatorcontrib><creatorcontrib>Cheng, S C</creatorcontrib><creatorcontrib>Wara, D W</creatorcontrib><title>Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>To test the hypothesis that serum levels of soluble markers in children change after initiation of zidovudine therapy and that the extent and pattern of these longitudinal changes correlates with clinical outcome. We measured serum levels of soluble CD8, neopterin, beta 2-microglobulin (beta 2M), and p24 antigen, and CD4 cell counts, before the initiation of zidovudine therapy and at 12, 24 and 48 weeks of treatment in 24 HIV-1-infected children (Centers for Disease Control classification P2) and 15 controls. Soluble CD8 levels were elevated before therapy in 70% of the infected children; subsequent decreases were associated with lower risk of disease progression. The mean serum neopterin level before treatment was elevated in infected children; decreases in neopterin levels marginally reflected improved or stable clinical status. Serum beta 2M levels and CD4+ cell counts were not associated with clinical outcome. Only 10 out of the 24 patients had detectable levels of serum p24 antigen before treatment; again, the amount of decline after initiation of therapy did not predict clinical outcome. Decreasing levels of soluble CD8 and neopterin in HIV-1-infected children receiving zidovudine therapy might reflect a good response to treatment and a slowing of disease progression.</description><subject>Acquired Immunodeficiency Syndrome - blood</subject><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>beta 2-Microglobulin - analysis</subject><subject>Biomarkers - blood</subject><subject>Biopterins - analogs &amp; derivatives</subject><subject>Biopterins - analysis</subject><subject>CD4-Positive T-Lymphocytes</subject><subject>CD8 Antigens - blood</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>HIV Core Protein p24 - blood</subject><subject>Humans</subject><subject>Infant</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Neopterin</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Zidovudine - therapeutic use</subject><issn>0269-9370</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotkE1OwzAQhb0AlVI4ApIP0MA4Thx7WbX8VKrEorCu7HjSGqVxZCdFcBfuigUdafT0ZuZ7iyGEMrhnoKoHSJUDh4wpxZMCZKkZXJAp5EJlildwRa5j_EjjEqSckIlMIKhySn62GMYjbfGEbaS-odG3o2mRLldyTjv0_YDBdXNqcNA0z46uDn7fejO2rqO6s7TPi6SD22PykbrOuloPPvylWRdRR6R9ggLG6HyXLmh9cK0NCfh0w4Eu1qstTYtvZ_1ptK5DOhww6P7rhlw2uo14e9YZeX96fFu-ZJvX5_Vyscl6xuWQCVaBBKG0MVDaQnBo0FbGQsNsoWqspKiRC9GYAlTOKiWM0ry0spal1Qr5jNz95_ajOaLd9cEddfjand_EfwEWxWuH</recordid><startdate>199303</startdate><enddate>199303</enddate><creator>Siller, L</creator><creator>Martin, N L</creator><creator>Kostuchenko, P</creator><creator>Beckett, L</creator><creator>Rautonen, J</creator><creator>Cheng, S C</creator><creator>Wara, D W</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>199303</creationdate><title>Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy</title><author>Siller, L ; Martin, N L ; Kostuchenko, P ; Beckett, L ; Rautonen, J ; Cheng, S C ; Wara, D W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p138t-61708069abb05d4630fed7bd0f1d49ce786ce366fb40921796b9a35d8c85da9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Acquired Immunodeficiency Syndrome - blood</topic><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>beta 2-Microglobulin - analysis</topic><topic>Biomarkers - blood</topic><topic>Biopterins - analogs &amp; derivatives</topic><topic>Biopterins - analysis</topic><topic>CD4-Positive T-Lymphocytes</topic><topic>CD8 Antigens - blood</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>HIV Core Protein p24 - blood</topic><topic>Humans</topic><topic>Infant</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Neopterin</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siller, L</creatorcontrib><creatorcontrib>Martin, N L</creatorcontrib><creatorcontrib>Kostuchenko, P</creatorcontrib><creatorcontrib>Beckett, L</creatorcontrib><creatorcontrib>Rautonen, J</creatorcontrib><creatorcontrib>Cheng, S C</creatorcontrib><creatorcontrib>Wara, D W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siller, L</au><au>Martin, N L</au><au>Kostuchenko, P</au><au>Beckett, L</au><au>Rautonen, J</au><au>Cheng, S C</au><au>Wara, D W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>1993-03</date><risdate>1993</risdate><volume>7</volume><issue>3</issue><spage>369</spage><pages>369-</pages><issn>0269-9370</issn><abstract>To test the hypothesis that serum levels of soluble markers in children change after initiation of zidovudine therapy and that the extent and pattern of these longitudinal changes correlates with clinical outcome. We measured serum levels of soluble CD8, neopterin, beta 2-microglobulin (beta 2M), and p24 antigen, and CD4 cell counts, before the initiation of zidovudine therapy and at 12, 24 and 48 weeks of treatment in 24 HIV-1-infected children (Centers for Disease Control classification P2) and 15 controls. Soluble CD8 levels were elevated before therapy in 70% of the infected children; subsequent decreases were associated with lower risk of disease progression. The mean serum neopterin level before treatment was elevated in infected children; decreases in neopterin levels marginally reflected improved or stable clinical status. Serum beta 2M levels and CD4+ cell counts were not associated with clinical outcome. Only 10 out of the 24 patients had detectable levels of serum p24 antigen before treatment; again, the amount of decline after initiation of therapy did not predict clinical outcome. Decreasing levels of soluble CD8 and neopterin in HIV-1-infected children receiving zidovudine therapy might reflect a good response to treatment and a slowing of disease progression.</abstract><cop>England</cop><pmid>8097095</pmid><doi>10.1097/00002030-199303000-00010</doi></addata></record>
fulltext fulltext
identifier ISSN: 0269-9370
ispartof AIDS (London), 1993-03, Vol.7 (3), p.369
issn 0269-9370
language eng
recordid cdi_pubmed_primary_8097095
source MEDLINE; Journals@Ovid Complete
subjects Acquired Immunodeficiency Syndrome - blood
Acquired Immunodeficiency Syndrome - drug therapy
beta 2-Microglobulin - analysis
Biomarkers - blood
Biopterins - analogs & derivatives
Biopterins - analysis
CD4-Positive T-Lymphocytes
CD8 Antigens - blood
Child
Child, Preschool
Female
HIV Core Protein p24 - blood
Humans
Infant
Leukocyte Count
Male
Neopterin
Predictive Value of Tests
Prospective Studies
Zidovudine - therapeutic use
title Serum levels of soluble CD8, neopterin, beta 2-microglobulin and p24 antigen as indicators of disease progression in children with AIDS on zidovudine therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A09%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20levels%20of%20soluble%20CD8,%20neopterin,%20beta%202-microglobulin%20and%20p24%20antigen%20as%20indicators%20of%20disease%20progression%20in%20children%20with%20AIDS%20on%20zidovudine%20therapy&rft.jtitle=AIDS%20(London)&rft.au=Siller,%20L&rft.date=1993-03&rft.volume=7&rft.issue=3&rft.spage=369&rft.pages=369-&rft.issn=0269-9370&rft_id=info:doi/10.1097/00002030-199303000-00010&rft_dat=%3Cpubmed%3E8097095%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8097095&rfr_iscdi=true